RxDoctor Payments DataLook up a doctor →

Rebecca McGowan, PA

Medical · Asheville, NCNPI 1851379952

Payments from drug & device makers

$13,461in general payments, 2019–2025

Across 612 payments — averaging $21.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • MDD US Operations, LLC$923
  • Livanova USA, Inc.$840
  • Teva Pharmaceuticals USA, Inc.$756
  • UCB, Inc.$645
  • AstraZeneca$590
  • plus $8K from 54 others

What the payments were for

  • Speaking & faculty fees$5384%
  • Travel & lodging$7546%
  • Food & beverage$12,12590%
  • Education$430%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)165$1,698
MDD US Operations, LLC12$923
Livanova USA, Inc.3$840
Teva Pharmaceuticals USA, Inc.15$756
UCB, Inc.23$645
AstraZeneca(2 entities)24$590
Biogen30$586
Novartis32$493
TG Therapeutics, Inc.10$422
Neurocrine Biosciences, Inc.12$293
Catalyst Pharmaceuticals, Inc.12$280
Amgen(2 entities)13$277
Argenx US, Inc.8$270
Sanofi9$232
Bristol Myers Squibb12$230
SK Life Science, Inc.8$209
Merz Pharmaceuticals, LLC9$206
E.r. Squibb & Sons, L.L.C.5$198
Amneal Pharmaceuticals LLC10$196
Eisai Inc.9$194
Jazz Pharmaceuticals Inc.7$193
Pfizer10$192
Lilly USA, LLC10$192
EMD Serono, Inc.6$189
Ipsen Biopharmaceuticals, Inc8$180
Johnson & Johnson(2 entities)8$176
Acadia Pharmaceuticals Inc7$164
Mallinckrodt Hospital Products Inc.6$152
Averitas Pharma Inc.6$131
Avanir Pharmaceuticals, Inc.7$130
Genentech USA, Inc.7$119
Sunovion Pharmaceuticals Inc.9$118
Lundbeck LLC6$104
Acorda Therapeutics, Inc5$100
Neurelis, Inc.3$97
Abbott6$96
Supernus Pharmaceuticals, Inc.4$87
Otsuka America Pharmaceutical, Inc.4$87
Biohaven Pharmaceuticals, Inc.6$86
Sumitomo Pharma America, Inc.5$83
CSL Behring3$78
Alnylam Pharmaceuticals Inc.3$75
Banner Life Sciences, LLC3$69
Greenwich Biosciences, Inc.4$68
Upsher-smith Laboratories LLC3$63
Takeda Pharmaceuticals U.S.A., Inc.2$59
Insightec,inc2$57
Adamas Pharmaceuticals, Inc.3$57
Biohaven Pharmaceutical Holding Company Ltd.3$56
Kyowa Kirin, Inc.3$53
ANI Pharmaceuticals, Inc.3$48
Axsome Therapeutics, Inc.2$48
Novo Nordisk1$48
Vanda Pharmaceuticals Inc.2$48
Tanabe Pharma America, Inc.2$47
Impel Pharmaceuticals LLC2$46
Mylan Specialty L.p.2$42
GRT US Holding, Inc.4$41
Cala Health, Inc.2$33
Xeris Pharmaceuticals, Inc.2$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,461 in reported general payments places this provider in the 95th percentile of 878 medical providers in North Carolina.

See all medical providers in North Carolina

Medicare billing

Part B allowed, 2024
$21,305
Medicare patients
73
Services billed
1,926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant69$103,583
Gamunex-CImmune Globul G/Gly/Iga Avg 4615$93,969
Emgality PenGalcanezumab-Gnlm101$89,296
Nurtec OdtRimegepant Sulfate42$61,752
Ajovy AutoinjectorFremanezumab-Vfrm46$44,273
EpidiolexCannabidiol (Cbd)12$44,263
LamictalLamotrigine45$43,654
Aimovig AutoinjectorErenumab-Aooe53$41,580
Topiramate ErTopiramate19$33,147
Lamictal XrLamotrigine12$29,031
BriviactBrivaracetam17$28,958
Dimethyl Fumarate11$28,408
FycompaPerampanel25$25,529
KeppraLevetiracetam16$24,936
Lacosamide96$23,113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Linzess$1,698$111,86786 claims
PfizerNurtec Odt, Zavzpret, Dilantin$192$81,84773 claims
UCB, Inc.Briviact, Nayzilam$645$43,94430 claims
Eisai Inc.Fycompa$194$25,52925 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$196$23,64856 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$87$22,04012 claims
Sunovion Pharmaceuticals Inc.Aptiom$118$14,39312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 medical providers in North Carolina.

Other medical in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →